Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Individualization of Factor VIII dosage.

A Messori, G Longo, M Morfini

    Journal of Clinical and Hospital Pharmacy
    |June 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Treatments for relapsed-refractory diffuse large B-cell lymphoma: comparison of overall survival outcomes observed with four novel agents.

    European review for medical and pharmacological sciences·2022
    Same author

    Restricted mean survival time in advanced non-small cell lung cancer treated with immune checkpoint inhibitors.

    European review for medical and pharmacological sciences·2021
    Same author

    Incidence of low-titre factor VIII inhibitors in patients with haemophilia A: meta-analysis of observational studies.

    Haemophilia : the official journal of the World Federation of Hemophilia·2017
    Same author

    Meta-Analysis: Limits and Benefits.

    Clinical drug investigation·2016
    Same author

    Effectiveness of Immunoglobulins for the Prevention of Systemic Infections : A Meta-Analysis of 8 Clinical Studies in Premature Infants.

    Clinical drug investigation·2016
    Same author

    Mutation spectrum of the MTM1 gene in XLMTM patients: 10 years of experience in prenatal and postnatal diagnosis.

    Clinical genetics·2015

    A new calculator program effectively individualizes Factor VIII dosage for hemophilia patients. This tool accurately predicts Factor VIII plasma levels, improving treatment regimens.

    Area of Science:

    • Hematology
    • Pharmacokinetics
    • Medical Informatics

    Background:

    • Hemophilia A requires precise Factor VIII replacement therapy.
    • Individual patient variability necessitates personalized dosing strategies.
    • Accurate pharmacokinetic modeling is crucial for optimizing treatment.

    Purpose of the Study:

    • To assess the utility of a calculator program for individualizing Factor VIII dosage.
    • To validate the program's ability to predict steady-state Factor VIII concentrations.
    • To improve therapeutic outcomes in hemophilia patients through tailored dosing.

    Main Methods:

    • A calculator program was developed to individualize Factor VIII dosage.
    • Individual pharmacokinetic parameters were estimated from test-dose plasma concentration-time data.

    Related Experiment Videos

  • 12 hemophilia patients received Factor VIII based on the program's suggested regimen.
  • Predicted steady-state Factor VIII levels were compared to measured levels.

    • Main Results:

    • The calculator program accurately predicted steady-state Factor VIII concentrations.
    • A strong correlation was observed between predicted and measured levels (r² = 0.9797; P < 0.001).
    • The program demonstrated high precision in individualizing Factor VIII dosing.

    Conclusions:

    • The calculator program is a valuable tool for personalized Factor VIII dosage in hemophilia.
    • Individualized dosing regimens enhance treatment efficacy and patient management.
    • This approach offers a promising method for optimizing Factor VIII therapy.